Aminothienopyridazines and methylene blue affect Tau fibrillization via cysteine oxidation

Journal of Biological Chemistry

Volumn 288, Issue 16, 2013, Pages 11024-11037

  Crowe, Alex ^a   James, Michael J ^a   Virginia M Y Lee, ^a   Smith III, Amos B ^b   Trojanowski, John Q ^a   Ballatore, Carlo ^a,b   Brunden, Kurt R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISULFIDE BOND FORMATION; FIBRIL FORMATION; FIBRILLIZATION; METHYLENE BLUE; OXIDATIVE MECHANISM; THERAPEUTIC AGENTS;

AMINO ACIDS; COVALENT BONDS;

AROMATIC COMPOUNDS;

AMINOTHIENOPYRIDAZINE DERIVATIVE; CENTRAL NERVOUS SYSTEM AGENTS; CNDR 51345; CNDR 51347; CNDR 51348; CNDR 51349; CNDR 51374; CNDR 51449; CYSTEINE; DIMER; DISULFIDE; METHYLENE BLUE; MONOMER; PYRIDAZINE DERIVATIVE; TAU PROTEIN; UNCLASSIFIED DRUG;

AMINO ACID METABOLISM; ARTICLE; CONTROLLED STUDY; DISULFIDE BOND; DRUG STRUCTURE; DRUG SYNTHESIS; IN VITRO STUDY; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN MODIFICATION; TAU FIBRILLIZATION;

ALZHEIMER DISEASE; CYSTEINE; HUMANS; METHYLENE BLUE; MULTIPROTEIN COMPLEXES; OXIDATION-REDUCTION; TAU PROTEINS;

EID: 84876588286     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.436006     Document Type: Article

References (52)

1. Kidd, M. (1963) Paired helical filaments in electron microscopy of Alzheimers disease. Nature 197, 192-193.
2. Lee, V. M., Balin, B. J., Otvos, L., Jr., and Trojanowski, J. Q. (1991) A68, a major subunit of paired helical filaments and derivatized forms of normal Tau. Science 251, 675-678.
3. Ballatore, C., Lee, V. M., and Trojanowski, J. Q. (2007) Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat. Rev. Neurosci. 8, 663-672.
4. Lee, V. M., Goedert, M., and Trojanowski, J. Q. (2001) Neurodegenerative tauopathies. Annu. Rev. Neurosci. 24, 1121-1159.
5. Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., Hackett, J., Adamson, J., Lincoln, S., Dickson, D., Davies, P., Petersen, R. C., Stevens, M., de Graaff, E., Wauters, E., van Baren, J., Hillebrand, M., Joosse, M., Kwon, J. M., Nowotny, P., Che, L. K., Norton, J., Morris, J. C., Reed, L. A., Trojanowski, J., Basun, H., Lannfelt, L., Neystat, M., Fahn, S., Dark, F., Tannenberg, T., Dodd, P. R., Hayward, N., Kwok, J. B., Schofield, P. R., Andreadis, A., Snowden, J., Craufurd, D., Neary, D., Owen, F., Oostra, B. A., Hardy, J., Goate, A., van Swieten, J., Mann, D., Lynch, T., and Heutink, P. (1998) Association of missense and 5'-splice-site mutations in Tau with the inherited dementia FTDP-17. Nature 393, 702-705.
6. Hong, M., Zhukareva, V., Vogelsberg-Ragaglia, V., Wszolek, Z., Reed, L., Miller, B. I., Geschwind, D. H., Bird, T. D., McKeel, D., Goate, A., Morris, J. C., Wilhelmsen, K. C., Schellenberg, G. D., Trojanowski, J. Q., and Lee, V. M. (1998) Mutation-specific functional impairments in distinct Tau isoforms of hereditary FTDP-17. Science 282, 1914-1917.
7. Cleveland, D. W., Hwo, S. Y., and Kirschner, M. W. (1977) Physical and chemical properties of purified Tau factor and role of Tau in microtubule assembly. J. Mol. Biol. 116, 227-247.
8. Cleveland, D. W., Hwo, S. Y., and Kirschner, M. W. (1977) Purification of tau, a microtubule-associated protein that induces assembly of microtubules from purified tubulin. J. Mol. Biol. 116, 207-225.
9. Wilcock, G. K., and Esiri, M. M. (1982) Plaques, tangles, and dementia. A quantitative study. J. Neurol. Sci. 56, 343-356.
10. Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., and Hyman, B. T. (1992) Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimers disease. Neurology 42, 631-639.
11. Braak, H., and Braak, E. (1991) Neuropathological staging of Alzheimerrelated changes. Acta Neuropathol. 82, 239-259.
12. Brunden, K. R., Trojanowski, J. Q., and Lee, V. M. (2008) Evidence that non-fibrillar Tau causes pathology linked to neurodegeneration and behavioral impairments. J. Alzheimers Dis. 14, 393-399.
13. Lee, V. M., Daughenbaugh, R., and Trojanowski, J. Q. (1994) Microtubule stabilizing drugs for the treatment of Alzheimers disease. Neurobiol. Aging 15, S87-S89.
14. Avila, J. (2006) Tau phosphorylation and aggregation in Alzheimer's disease pathology. FEBS Lett. 580, 2922-2927.
15. Brunden, K. R., Ballatore, C., Crowe, A., Smith, A. B., 3rd, Lee, V. M., and Trojanowski, J. Q. (2010) Tau-directed drug discovery for Alzheimer's disease and related tauopathies. A focus on Tau assembly inhibitors. Exp. Neurol. 223, 304-310.
16. Brunden, K. R., Trojanowski, J. Q., and Lee, V. M. (2009) Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. Nat. Rev. Drug Discov. 8, 783-793.
17. Margittai, M., and Langen, R. (2004) Template-assisted filament growth by parallel stacking of Tau. Proc. Natl. Acad. Sci. U.S.A. 101, 10278-10283.
18. Congdon, E. E., Kim, S., Bonchak, J., Songrug, T., Matzavinos, A., and Kuret, J. (2008) Nucleation-dependent Tau filament formation. The importance of dimerization and an estimation of elementary rate constants. J. Biol. Chem. 283, 13806-13816.
19. Chirita, C. N., Necula, M., and Kuret, J. (2003) Anionic micelles and vesicles induce Tau fibrillization in vitro. J. Biol. Chem. 278, 25644-25650.
20. Wilson, D. M., and Binder, L. I. (1997) Free fatty acids stimulate the polymerization of Tau and amyloid beta peptides. In vitro evidence for a common effector of pathogenesis in Alzheimer's disease. Am. J. Pathol. 150, 2181-2195.
21. Goedert, M., Jakes, R., Spillantini, M. G., Hasegawa, M., Smith, M. J., and Crowther, R. A. (1996) Assembly of microtubule-associated protein Tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans. Nature 383, 550-553.
22. Wille, H., Drewes, G., Biernat, J., Mandelkow, E. M., and Mandelkow, E. (1992) Alzheimer-like paired helical filaments and antiparallel dimers formed from microtubule-associated protein Tau in vitro. J. Cell Biol. 118, 573-584.
23. Ballatore, C., Brunden, K. R., Trojanowski, J. Q., Lee, V. M., Smith, A. B., 3rd, and Huryn, D. (2011) Modulation of protein-protein interactions as a therpeutic strategy for the treatment of neurodegenerative tauopathies. Curr. Top. Med. Chem. 11, 317-330.
24. Bulic, B., Pickhardt, M., Mandelkow, E. M., and Mandelkow, E. (2010) Tau protein and Tau aggregation inhibitors. Neuropharmacology 59, 276-289.
25. Staff, R. T., Ahearn, T. S., Murray, A. D., Benthan, P., Seng, K. M., and Wischik, C. (2008) Tau aggregation inhibitor (TAI) therapy with rember arrests the trajectory of rCBF decline in brain regions affected by Tau pathology in mild to moderate Alzheimer's disease. Alzheimer Dement. 4, T775.
26. Crowe, A., Huang, W., Ballatore, C., Johnson, R. L., Hogan, A. M., Huang, R., Wichterman, J., McCoy, J., Huryn, D., Auld, D. S., Smith, A. B., 3rd, Inglese, J., Trojanowski, J. Q., Austin, C. P., Brunden, K. R., and Lee, V. M. (2009) The identification of aminothienopyridazine inhibitors of Tau assembly by quantitative high-throughput screening. Biochemistry 48, 7732-7745.
27. Ballatore, C., Crowe, A., Piscitelli, F., James, M., Lou, K., Rossidivito, G., Yao, Y., Trojanowski, J. Q., Lee, V. M., Brunden, K. R., and Smith, A. B., 3rd (2012) Aminothienopyridazine inhibitors of Tau aggregation. Evaluation of structure-activity relationship leads to selection of candidates with desirable in vivo properties. Bioorg. Med. Chem. 20, 4451-4461.
28. Ballatore, C., Brunden, K. R., Piscitelli, F., James, M. J., Crowe, A., Yao, Y., Hyde, E., Trojanowski, J. Q., Lee, V. M., and Smith, A. B., 3rd (2010) Discovery of brain-penetrant, orally bioavailable aminothienopyridazine inhibitors of Tau aggregation. J. Med. Chem. 53, 3739-3747.
29. Li, W., Sperry, J. B., Crowe, A., Trojanowski, J. Q., Smith, A. B., 3rd, and Lee, V. M. (2009) Inhibition of Tau fibrillization by oleocanthal via reaction with the amino groups of Tau. J Neurochem. 110, 1339-1351.
30. Barghorn, S., and Mandelkow, E. (2002) Toward a unified scheme for the aggregation of Tau into Alzheimer paired helical filaments. Biochemistry 41, 14885-14896.
31. Barghorn, S., Zheng-Fischhöfer, Q., Ackmann, M., Biernat, J., von Bergen, M., Mandelkow, E. M., and Mandelkow, E. (2000) Structure, microtubule interactions, and paired helical filament aggregation by Tau mutants of frontotemporal dementias. Biochemistry 39, 11714-11721.
32. Tam, J. P., Wu, C. R., Liu, W., and Zhang, J. W. (1991) Disulfide bond formation in peptides by dimethyl sulfoxide. Scope and applications. J. Am. Chem. Soc. 113, 6657-6662.
33. Crowe, A., Ballatore, C., Hyde, E., Trojanowski, J. Q., and Lee, V. M. (2007) High throughput screening for small molecule inhibitors of heparin-induced Tau fibril formation. Biochem. Biophys. Res. Commun. 358, 1-6.
34. Zhang, J. H., Chung, T. D., and Oldenburg, K. R. (1999)Asimple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4, 67-73.
35. McLellan, T. (1982) Electrophoresis buffers for polyacrylamide gels at various pH. Anal. Biochem. 126, 94-99.
36. Gorman, J. J. (1987) Fluorescent labeling of cysteinyl residues to facilitate electrophoretic isolation of proteins suitable for amino-terminal sequence analysis. Anal. Biochem. 160, 376-387.
37. Walker, S., Ullman, O., and Stultz, C. M. (2012) Using intramolecular disulfide bonds in Tau protein to deduce structural features of aggregation-resistant conformations. J. Biol. Chem. 287, 9591-9600.
38. Schweers, O., Mandelkow, E. M., Biernat, J., and Mandelkow, E. (1995) Oxidation of cysteine 322 in the repeat domain of microtubule-associated protein Tau controls the in vitro assembly of paired helical filaments. Proc. Natl. Acad. Sci. U.S.A. 92, 8463-8467.
39. Ruddock, L. W., Hirst, T. R., and Freedman, R. B. (1996) pH dependence of the dithiol-oxidizing activity of DsbA (a periplasmic protein thiol:disulphide oxidoreductase) and protein disulphide-isomerase. Studies with a novel simple peptide substrate. Biochem. J. 315, 1001-1005.
40. 2 by redox cycling in reducing environments. Assay Drug Dev. Technol. 8, 152-174.
41. Taniguchi, S., Suzuki, N., Masuda, M., Hisanaga, S., Iwatsubo, T., Goedert, M., and Hasegawa, M. (2005) Inhibition of heparin-induced Tau filament formation by phenothiazines, polyphenols, and porphyrins. J. Biol. Chem. 280, 7614-7623.
42. Chang, E., Congdon, E. E., Honson, N. S., Duff, K. E., and Kuret, J. (2009) Structure-activity relationship of cyanine Tau aggregation inhibitors. J. Med. Chem. 52, 3539-3547.
43. Wischik, C. M., Edwards, P. C., Lai, R. Y., Roth, M., and Harrington, C. R. (1996) Selective inhibition of Alzheimer disease-like Tau aggregation by phenothiazines. Proc. Natl. Acad. Sci. U.S.A. 93, 11213-11218.
44. Oz, M., Lorke, D. E., Hasan, M., and Petroianu, G. A. (2011) Cellular and molecular actions of methylene blue in the nervous system. Med. Res. Rev. 31, 93-117.
45. Wainwright, M., and Crossley, K. B. (2002) Methylene Blue. A therapeutic dye for all seasons? J. Chemother. 14, 431-443.
46. Zhang, H., and Forman, H. J. (2012) Glutathione synthesis and its role in redox signaling. Semin. Cell Dev. Biol. 23, 722-728.
47. Smith, G. K., Barrett, D. G., Blackburn, K., Cory, M., Dallas, W. S., Davis, R., Hassler, D., McConnell, R., Moyer, M., and Weaver, K. (2002) Expression, preparation, and high-throughput screening of caspase-8. Discovery of redox-based and steroid diacid inhibition. Arch. Biochem. Biophys. 399, 195-205.
48. Hasegawa, M. (2006) Biochemistry and molecular biology of tauopathies. Neuropathology 26, 484-490.
49. Schirmer, R. H., Adler, H., Pickhardt, M., and Mandelkow, E. (2011) "Lest we forget you "methylene blue. " Neurobiol. Aging 32, 2325.
50. Jinwal, U. K., Miyata, Y., Koren, J., 3rd, Jones, J. R., Trotter, J. H., Chang, L., O'Leary, J., Morgan, D., Lee, D. C., Shults, C. L., Rousaki, A., Weeber, E. J., Zuiderweg, E. R., Gestwicki, J. E., and Dickey, C. A. (2009) Chemical manipulation of Hsp70 ATPase activity regulates Tau stability. J. Neurosci. 29, 12079-12088.
51. O'Leary, J. C., 3rd, Li, Q., Marinec, P., Blair, L. J., Congdon, E. E., Johnson, A. G., Jinwal, U. K., Koren, J., 3rd, Jones, J. R., Kraft, C., Peters, M., Abisambra, J. F., Duff, K. E., Weeber, E. J., Gestwicki, J. E., and Dickey, C. A. (2010) Phenothiazine-mediated rescue of cognition in Tau transgenic mice requires neuroprotection and reduced soluble Tau burden. Mol. Neurodegener. 5, 45.
52. Congdon, E. E., Wu, J. W., Myeku, N., Figueroa, Y. H., Herman, M., Marinec, P. S., Gestwicki, J. E., Dickey, C. A., Yu, W. H., and Duff, K. E. (2012) Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo. Autophagy 8, 609-622.